On June 25, 2026, FDA issued Warning Letter 320-26-98 to Excelvision (a Fareva facility) in Annonay, France, following an inspection conducted January 12 to 22, 2026 — the second warning letter this site has received in less than eighteen months. What FDA documented at the Annonay facility is not a collection of isolated deficiencies. It is a sterility assurance system in structural collapse, with nine non-sterility events over three years, facility infrastructure unsuitable for aseptic manufacturing, and a remediation history that failed to hold.
The primary citation in Warning Letter 320-26-98 is 21 CFR 211.192 — failure to thoroughly investigate unexplained discrepancies or failures to meet specifications. The violations FDA documented at Excelvision are not procedural. They reveal an investigation culture that defaulted to blaming customers when its own environmental monitoring data contained the answer. In one case that FDA specifically cited, a complaint sample sterility failure yielded Alternaria alternata. The same organism had been recovered in environmental and personnel monitoring samples collected before and after the implicated batch was manufactured — including in the filling room where that batch was produced. The complaint investigation report contained none of this information. Alternaria alternata is an environmental mold; its presence across EM/PM data and a failed complaint sample in the same manufacturing period is not coincidence. It is a contamination source signal that a functional investigation system should have resolved. Instead, the firm attributed most of its contamination complaints to inadequate handling by end users and closed the investigations without corrective action.
The sterility risk at this facility is compounded by infrastructure that is fundamentally unsuitable for aseptic manufacturing. Under 21 CFR 211.42(c)(10)(i), aseptic processing areas must have smooth, hard surfaces that are easily cleanable. FDA inspectors documented that ceilings and partitions in classified areas of the Annonay facility — including filling rooms, compounding rooms, machine part washing rooms, and the weighing area — are constructed of a material the firm itself described as “not waterproof” and “cannot be decontaminated.” Between January 2024 and January 2026, the facility experienced numerous water incursions into these classified areas. Mold recoveries from routine production EM data between January 2024 and March 2025 followed directly from those incursions. Any water ingress event in an aseptic processing cleanroom is an uncontrolled bioburden introduction event. Repeat incursions through non-waterproof overhead surfaces in classified areas represent not a maintenance deficit but a fundamental incompatibility between the facility’s materials of construction and its intended manufacturing purpose.
The aseptic behavior findings cited under 21 CFR 211.113(b) are equally serious. During filling line setup, personnel blocked unidirectional airflow to the ISO 5 zone with their gloves during installation of line components. An operator conducting line clearance after setup leaned their head and torso through the barrier into the ISO 5 filling area. Critical equipment on the line — specifically, components adjacent to the open sterile product exposure path — blocked unidirectional airflow over the fill bowl and the closure handling zone. Unidirectional airflow in an ISO 5 environment is not a regulatory formality. Its function is to maintain a continuous laminar curtain of HEPA-filtered air that sweeps contamination away from the exposed critical zone. An operator’s body entering that curtain at the fill point creates a stagnation zone where microbial-carrying particles carried from the lower-classified surroundings can accumulate. The FDA 2004 Aseptic Processing Guidance is explicit: aseptic manufacturing processes must be designed and executed to prevent contamination hazards, and equipment design that impedes unidirectional airflow over product-contact surfaces is a CGMP violation regardless of whether a contamination event is linked to it.
FDA also cited 21 CFR 211.42(c)(10)(v) — an inadequate system for cleaning and disinfecting the room and equipment. Excelvision’s aseptic process did not include between-batch sterilization of critical equipment components such as the fill bowls and closure handling parts; instead, it relied on sporicide disinfection of the ISO 5 filling lines. There is a material difference between disinfection and sterilization for components in direct contact with sterile product or its containers and closures. Sterilization assures the absence of viable organisms to a specified sterility assurance level. Disinfection does not. For product-contact components in an ISO 5 environment, disinfection alone does not meet the contamination control standard established by the FDA 2004 Aseptic Processing Guidance and EU GMP Annex 1 (2023 revision).
The enforcement consequences are severe and immediate. FDA placed all drugs and drug products offered for import into the United States from the Annonay facility on Import Alert 66-40 on April 27, 2026. Between the inspection and the import alert, Excelvision issued voluntary recalls of all sterile drug products then in US distribution due to lack of sterility assurance. The firm has committed to cease and suspend production on multiple filling lines, and to replace two aseptic processing lines entirely. For a contract manufacturer supplying sterile ophthalmics and other sterile products to US-market drug product owners, the commercial impact extends far beyond the facility itself — every product owner relying on Annonay production must now manage supply discontinuity while the facility undertakes a remediation program whose scope FDA has already described as inadequate.
For sterile drug product manufacturers and their supply chain partners, the Excelvision Warning Letter carries several specific lessons. First, complaint sterility failures must be cross-referenced against contemporaneous EM/PM data in the same manufacturing period before any root cause can be closed. The presence of Alternaria alternata in both a failed complaint sample and the facility’s own EM data from the same fill room is not ambiguous data — it is a root cause signal that required investigation under 21 CFR 211.192 and 211.198. Second, facility infrastructure that cannot be decontaminated is not a compliant aseptic manufacturing environment, regardless of procedural controls layered over it. Water-permeable ceiling materials in classified areas must be replaced, not managed. Third, repeat warnings from FDA — this is the second warning letter for this facility in eighteen months — with recurrence of similar violations demonstrate that corrective actions were neither effective nor durable, the precise language FDA used in the letter.
Companies managing sterile product supply chains or undergoing environmental monitoring trend excursions in classified areas should assess whether their investigation procedures require contemporaneous cross-referencing of EM/PM organism identifications against complaint microbiology results. XGene’s contamination control and sterility assurance advisory practice works with sterile product manufacturers to build investigation systems that connect environmental monitoring data, media fill history, and product complaint outcomes into a unified contamination trending framework — the kind of integrated picture that would have resolved the Alternaria signal at Annonay before nine non-sterility events accumulated over three years.